Value proposition

Revolutionizing early diagnosis of Ovarian Cancer

AOA Dx is developing the next frontier in early-stage cancer detection for women through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, GlycoLocateTM, is paving the way for life-saving early cancer detection. In a first of its kind, AOA Dx is developing AKRIVIS GDTM, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers. AOA Dx was co-founded by three experts and passionate advocates of women’s health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization.

AOA Dx, a Y combinator and VC backed company, raised an oversubscribed Seed Round to accelerate development and clinical studies.

Awards & Accelerators:
1. Y Combinator
2. MassChallenge
3. Springboard Enterprises
4. MassMedic Ignite
5. Inc Magazine Top 100 Female Founders
6. Women's Health Innovation Summit Award
7. Massachusetts Life Sciences Center MassNextGen Award
8. The Wave Summit's Emerging Women Founder in Bio Award
9. The Eddies Award
10. Bloomberg New Economy Catalyst


www.aoadx.com

Medical Devices, Diagnostics, Prognostics, Biotechnology, Sales, Commercialization, Regulatory, Licensing, Quality, FDA, IVD, CE IVDR, Ovarian Cancer, Women's Health, Cancer Diagnostics, and Liquid Biopsy